# Semaglutide (oral) PIONEER 6: heart safety in diabetes

Source: https://pepvault.app/research/semaglutide-oral-pioneer-6-2019

Last updated: 2026-11-17

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Research](https://pepvault.app/research) [Semaglutide (oral)](https://pepvault.app/research#semaglutide-oral)

Randomized trial · people

# Semaglutide (oral): heart risk not higher than placebo in PIONEER 6

Checked against the paper November 2026 Randomized trial [Published by PepVault](https://pepvault.app/guides/how-we-research)

## The takeaway

In people with type 2 diabetes at high heart risk, oral semaglutide met the trial's test for not adding heart risk compared with placebo. More people on it stopped treatment because of stomach and gut side effects.

- **Kind:** Randomized trial
- **Studied in:** People
- **Number studied:** 3183
- **Published:** 2019
- **Journal:** N Engl J Med

## What they tested

The team tested whether once-daily oral semaglutide raises the risk of major heart events in people with type 2 diabetes compared with placebo, a dummy pill.

## How the study was done

A randomized, double-blind, placebo-controlled trial in 3183 people with type 2 diabetes at high heart risk. They were age 50 or older with heart or chronic kidney disease, or age 60 or older with heart risk factors only. People were followed for a median of 15.9 months, and the trial was set up to rule out a heart risk 80% higher than with placebo.

<!--promo-->

Model. Individual results vary.

PepVault for iPhone

## Taking Semaglutide (oral)? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=study-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## What they found

Major heart events occurred in 61 of 1591 people (3.8%) on oral semaglutide and 76 of 1592 (4.8%) on placebo. These events were heart-related death, a nonfatal heart attack or a nonfatal stroke. The hazard ratio, a measure of relative risk over time, was 0.79 (95% CI 0.57 to 1.11), which met the trial's goal of showing no excess risk (P<0.001). Heart-related death occurred in 0.9% vs 1.9% (hazard ratio 0.49), death from any cause in 1.4% vs 2.8% (hazard ratio 0.51), nonfatal heart attacks in 2.3% vs 1.9%, and nonfatal strokes in 0.8% vs 1.0%. Stomach and gut side effects that led people to stop treatment were more common with oral semaglutide.

## What it doesn’t show

The trial was built to rule out added heart risk, not to prove a reduction, and its median follow-up was 15.9 months. It was funded by Novo Nordisk.

## The paper

Husain et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019.

- [PubMed (PMID 31185157)](https://pubmed.ncbi.nlm.nih.gov/31185157/)
- [The paper (DOI 10.1056/NEJMoa1901118)](https://doi.org/10.1056/NEJMoa1901118)
- [ClinicalTrials.gov (NCT02692716)](https://clinicaltrials.gov/study/NCT02692716)

## The compounds

- [Semaglutide (oral): how it works, half-life, studied range and evidence](https://pepvault.app/peptides/semaglutide-oral)
- [Semaglutide: how it works, half-life, studied range and evidence](https://pepvault.app/peptides/semaglutide)
- [Semaglutide (oral) dose guide](https://pepvault.app/lab/dosage/semaglutide-oral)
- [Semaglutide dose guide](https://pepvault.app/lab/dosage/semaglutide)

## With this study

### Semaglutide (oral)

- [Semaglutide (oral): the full reference](https://pepvault.app/peptides/semaglutide-oral)
- [Semaglutide (oral) dose guide](https://pepvault.app/lab/dosage/semaglutide-oral)

### Semaglutide

- [Semaglutide: the full reference](https://pepvault.app/peptides/semaglutide)
- [Semaglutide dose guide](https://pepvault.app/lab/dosage/semaglutide)

### Mixing charts

- [Semaglutide 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)
- [Semaglutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-5mg)
- [Semaglutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-10mg)

### Studies

- [Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3](https://pepvault.app/research/semaglutide-achieve-3-2026)
- [Semaglutide (oral) did not slow early Alzheimer's in evoke trials](https://pepvault.app/research/semaglutide-oral-evoke-and-evoke-2026)
- [Semaglutide 25 mg pill: 13.6% weight loss at 64 weeks in OASIS 4](https://pepvault.app/research/semaglutide-oasis-4-2025)
- [All 5 studies](https://pepvault.app/research#semaglutide-oral)
- [CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5](https://pepvault.app/research/cagrisema-redefine-5-2026)
- [All 20 studies](https://pepvault.app/research#semaglutide)

### Compared with

- [Semaglutide vs Semaglutide (oral)](https://pepvault.app/peptides/compare/semaglutide-vs-semaglutide-oral)
- [Orforglipron vs Semaglutide (oral)](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide-oral)
- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Orforglipron vs Semaglutide](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide)
- [Cagrilintide vs Semaglutide](https://pepvault.app/peptides/compare/cagrilintide-vs-semaglutide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### Terms on this page

- [Placebo](https://pepvault.app/glossary/placebo)

## More studies on Semaglutide (oral)

- [Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3](https://pepvault.app/research/semaglutide-achieve-3-2026) Randomized trial · people · 2026
- [Semaglutide (oral) did not slow early Alzheimer's in evoke trials](https://pepvault.app/research/semaglutide-oral-evoke-and-evoke-2026) Randomized trial · people · 2026
- [Semaglutide 25 mg pill: 13.6% weight loss at 64 weeks in OASIS 4](https://pepvault.app/research/semaglutide-oasis-4-2025) Randomized trial · people · 2025
- [Semaglutide pill: 15.1% weight loss at 68 weeks in OASIS 1](https://pepvault.app/research/semaglutide-oasis-1-2023) Randomized trial · people · 2023
- [Every study on Semaglutide (oral)](https://pepvault.app/research#semaglutide-oral)

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed November 2026. Spot an error? [feedback@pepvault.app](mailto:feedback@pepvault.app). [How we research](https://pepvault.app/guides/how-we-research). This page reports one study; it is not medical advice.

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=study-card-next&mt=8)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Taking Semaglutide (oral)? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=study-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

<!--promo-->

Model. Individual results vary.

PepVault for iPhone

## Taking Semaglutide (oral)? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=study-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this study

### Semaglutide (oral)

- [Semaglutide (oral): the full reference](https://pepvault.app/peptides/semaglutide-oral)
- [Semaglutide (oral) dose guide](https://pepvault.app/lab/dosage/semaglutide-oral)

### Semaglutide

- [Semaglutide: the full reference](https://pepvault.app/peptides/semaglutide)
- [Semaglutide dose guide](https://pepvault.app/lab/dosage/semaglutide)

### Mixing charts

- [Semaglutide 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)
- [Semaglutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-5mg)
- [Semaglutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-10mg)

### Studies

- [Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3](https://pepvault.app/research/semaglutide-achieve-3-2026)
- [Semaglutide (oral) did not slow early Alzheimer's in evoke trials](https://pepvault.app/research/semaglutide-oral-evoke-and-evoke-2026)
- [Semaglutide 25 mg pill: 13.6% weight loss at 64 weeks in OASIS 4](https://pepvault.app/research/semaglutide-oasis-4-2025)
- [All 5 studies](https://pepvault.app/research#semaglutide-oral)
- [CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5](https://pepvault.app/research/cagrisema-redefine-5-2026)
- [All 20 studies](https://pepvault.app/research#semaglutide)

### Compared with

- [Semaglutide vs Semaglutide (oral)](https://pepvault.app/peptides/compare/semaglutide-vs-semaglutide-oral)
- [Orforglipron vs Semaglutide (oral)](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide-oral)
- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Orforglipron vs Semaglutide](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide)
- [Cagrilintide vs Semaglutide](https://pepvault.app/peptides/compare/cagrilintide-vs-semaglutide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### Terms on this page

- [Placebo](https://pepvault.app/glossary/placebo)

<!--promo-->

PepVault for iPhone

## Taking Semaglutide (oral)? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=study-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## Research

- [All studies](https://pepvault.app/research)
- [Every study on Semaglutide (oral)](https://pepvault.app/research#semaglutide-oral)

## The library

- [Semaglutide (oral)](https://pepvault.app/peptides/semaglutide-oral)
- [Semaglutide (oral) dose guide](https://pepvault.app/lab/dosage/semaglutide-oral)
- [Semaglutide](https://pepvault.app/peptides/semaglutide)
- [Semaglutide dose guide](https://pepvault.app/lab/dosage/semaglutide)
- [The peptide reference library](https://pepvault.app/peptides)

## How we work

- [How we research](https://pepvault.app/guides/how-we-research)
- [How we check the library](https://pepvault.app/about#library)

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it. Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Saxenda, Victoza and Trulicity are trademarks of their respective owners; PepVault is independent and not affiliated with or endorsed by any manufacturer.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
